Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics Chief Operating Officer receives new equity awards. On February 4, 2026, David Lee Johnson was granted 20,000 restricted stock units of Class A Common Stock at a price of $0 under Vera’s 2021 Equity Incentive Plan and 40,000 stock options with an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, assuming continued service. The stock options begin vesting on March 4, 2026, with 1/48th of the grant vesting monthly, also conditioned on continued service. Following the RSU grant, he beneficially owns 48,306 Class A shares directly.
Vera Therapeutics Chief Medical Officer granted RSUs and stock options
Vera Therapeutics’ Chief Medical Officer, Robert Brenner, reported equity awards dated February 4, 2026. He received 25,000 shares of Class A common stock in the form of restricted stock units, granted at $0 cost. These RSUs vest in four equal annual installments on February 20, 2027, 2028, 2029 and 2030, if he remains in continuous service.
He also received a stock option for 50,000 shares of Class A common stock at an exercise price of $42.74 per share, expiring on February 3, 2036. One forty‑eighth of the option vests on March 4, 2026, with the remainder vesting monthly thereafter, subject to continued service. After these transactions, Brenner directly beneficially owns 53,098 shares of Class A common stock.
FMR LLC and Abigail P. Johnson reported their holdings of Vera Therapeutics Inc. Class A common stock on an amended Schedule 13G. They report beneficial ownership of 2,885,853 shares, representing 4.1% of the class.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. FMR LLC has sole voting power over 2,878,610 shares and sole dispositive power over 2,885,853 shares, while Abigail P. Johnson reports sole dispositive power over the same 2,885,853 shares.
Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.
He also holds stock options for 60,000 shares at an exercise price of $41.75 expiring on 10/01/2034 and 31,500 shares at $29.18 expiring on 02/17/2035. These options vest monthly over time, following initial partial vesting completed in January 2026.
The Vanguard Group reported beneficial ownership of 3,570,401 shares of Vera Therapeutics Inc. common stock, representing 5.03% of the outstanding class as of the event date. All shares are held with shared voting and dispositive power through Vanguard-managed client accounts.
Vanguard reports shared voting power over 489,258 shares and shared dispositive power over the full 3,570,401 shares, with no sole voting or dispositive authority. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics.
Vera Therapeutics, Inc. reported a leadership change, stating that Jason Carter will no longer serve as the company’s Chief Legal Officer, effective December 24, 2025. The change was disclosed as an officer departure under a current report, with no additional details provided about his future role or any replacement.
Vera Therapeutics’ Chief Regulatory Officer reported an option exercise and share sale. On December 15, 2025, the officer exercised a stock option to buy 10,000 shares of Class A common stock at $15.53 per share, then sold 10,000 shares of Class A common stock in the open market at a weighted average price of $50.0767 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, the officer directly owned 22,500 shares of Class A common stock and held 245,000 stock options directly.
Vera Therapeutics, Inc. reported an insider share purchase by a director. On 12/11/2025, the reporting person bought 5,882 shares of Class A common stock at $42.5 per share and now directly holds 5,882 shares.
The filing also describes large indirect holdings through investment funds. Longitude Prime Fund, L.P. holds 1,797,619 shares and Longitude Venture Partners IV, L.P. holds 3,596,593 shares. The reporting person, related general partner entities and another managing member may be deemed to share voting and dispositive power over these fund-held shares, while each disclaims beneficial ownership except to the extent of their pecuniary interests.
Vera Therapeutics is offering $200,000,000 of its Class A common stock in a primary public offering, and has granted underwriters an option to buy up to an additional $30,000,000 of shares. The company plans to use the cash, together with existing funds and its Oxford loan facility, to fund the potential commercial launch of its lead drug atacicept for IgA nephropathy, expand atacicept into new clinical indications, and support general corporate purposes such as working capital and capital spending.
Vera is a late clinical-stage biotechnology company focused on serious immunological diseases. Atacicept has shown positive Phase 2b results in IgA nephropathy, a pivotal Phase 3 trial has completed enrollment, and a Biologics License Application was submitted to the FDA through the Accelerated Approval Program on November 7, 2025. Management believes proceeds from this deal, combined with existing resources, will be sufficient to fund projected operating requirements through a potential 2026 U.S. launch of atacicept in IgA nephropathy, if approved, but investors face immediate dilution, no expected dividends, and risks around market liquidity and broad management discretion over how proceeds are spent.
Vera Therapeutics, Inc. (VERA) reported a stock option grant to a director on 11/25/2025. The filing shows a stock option to purchase 25,000 shares of Class A common stock at an exercise price of $29.43 per share, expiring on 11/24/2035.
The option will vest monthly over a three-year period, as long as the director continues to serve through each vesting date. The filing also states that all shares subject to the option will vest in full if there is a change in control, provided the director remains in continuous service through the date of that change in control.